Waters Corp. shares are higher as investors react to a recent analyst upgrade that put the name back in focus ahead of the company’s next earnings event. Evercore ISI upgraded Waters to Outperform and attached a $350 price target, helping drive a renewed bid in the stock into the next catalyst window. (marketbeat.com)

Waters has scheduled its first-quarter 2026 financial results conference call for Tuesday, May 5, 2026 at 8:30 a.m. ET, putting the stock in a classic pre-earnings setup where incremental upgrades and positioning can move prices quickly. With the company now framed as a larger life sciences and diagnostics platform, traders are also watching how management characterizes demand trends and early integration execution. (ir.waters.com)

Sentiment around Waters’ 2026 outlook has been tightly linked to integration execution and the combined-company growth profile following the addition of BD’s Biosciences and Diagnostic Solutions business. In its latest annual results update, Waters outlined 2026 expectations that include both organic growth and a large acquired revenue contribution, which makes the upcoming quarter an important checkpoint for cadence, margins, and synergy progress. (ir.waters.com)

Key watch items for the May 5 call include revenue growth versus the company’s prior first-quarter outlook range, any changes to full-year 2026 non-GAAP EPS expectations, and evidence that commercial initiatives (service attachment, e-commerce, and instrument replacement cycle execution) are translating into durable demand. If management commentary reduces perceived integration risk, the market’s multiple on the combined business can expand; if not, the stock may remain headline-sensitive into the next milestones. (ir.waters.com)